Trizepatide

The Trizepatide (tirzepatide) 30 mg protocol describes the same core incretin biology as other vial sizes: it is a dual agonist at GLP-1 and GIP receptors. The page explains that receptor co-activation improves glucose control by increasing insulin secretion in a glucose-dependent manner and lowering glucagon output, while also slowing gastric emptying and enhancing satiety via central appetite pathways. The protocol emphasizes that GIP agonism may synergize with GLP-1 effects to produce greater metabolic improvements and weight reduction than GLP-1 agonism alone. Its long half-life (around 5 days) is presented as enabling a weekly schedule with consistent receptor engagement across the week. The overall mechanism is framed as simultaneously targeting appetite, gastric emptying, and endocrine glucose regulation—so the outcome is both improved glycemic markers and meaningful body-weight reduction, tempered by dose-dependent gastrointestinal tolerability.